Table 2.
Univariate Cox proportional hazard models for PFS and OS.
| Variable | PFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | Univariate 95% CI | p | HR | Univariate 95% CI | p | |
| Age | ||||||
| <65 | Ref | Ref | ||||
| ≥65 | 0.46 | 0.14–1.47 | 0.19 | 2.41 | 0.57–10.18 | 0.23 |
| ECOG PS | ||||||
| 0 | Ref | Ref | ||||
| 1–2 | 1.73 | 0.73–4.10 | 0.21 | 0.38 | 0.13–1.11 | 0.07 |
| Smoking status | ||||||
| Non-smoker/Former smoker | Ref | Ref | ||||
| Current | 0.67 | 0.27–1.65 | 0.39 | 0.21 | 0.71–0.62 | 0.005 |
| BMI | ||||||
| <25 | Ref | Ref | ||||
| ≥25 | 2.44 | 0.92–6.34 | 0.07 | 0.29 | 0.07–1.13 | 0.07 |
| Comorbidity | ||||||
| Absent | Ref | Ref | ||||
| Present | 2.73 | 1.10–6.81 | 0.03 | 0.57 | 0.14–2.22 | 0.41 |
| Histology | ||||||
| Non-squamous | Ref | Ref | ||||
| Squamous | 0.50 | 0.20–1.29 | 0.15 | 0.81 | 0.20–3.20 | 0.76 |
| PDL-1 | ||||||
| Negative | Ref | Ref | ||||
| Positive | 1.07 | 0.47–2.47 | 0.85 | 0.59 | 0.21–1.61 | 0.30 |
| Metastasis at diagnosis | ||||||
| Non-metastasis | Ref | Ref | ||||
| De novo metastasis | 1.27 | 0.23–6.84 | 0.77 | 11.67 | 0.85–159.57 | 0.06 |
| Median number of cycles of nivolumab treatment | ||||||
| ≤8 | Ref | Ref | ||||
| 8< | 0.02 | 0.00–0.12 | 0.0001 | 0.98 | 0.22–4.28 | 0.98 |
| PIV | ||||||
| Low | Ref | Ref | ||||
| High | 1.14 | 0.14–8.88 | 0.90 | 2.88 | 0.38–21.52 | 0.30 |
| SII | ||||||
| Low | Ref | Ref | ||||
| High | 0.66 | 0.07–6.15 | 0.72 | 0.26 | 0.02–3.31 | 0.30 |
| NLR | ||||||
| Low | Ref | Ref | ||||
| High | 0.96 | 0.27–3.36 | 0.96 | 2.87 | 0.74–11.15 | 0.12 |
| PLR | ||||||
| Low | Ref | Ref | ||||
| High | 1.43 | 0.44–4.68 | 0.54 | 0.49 | 0.08–2.99 | 0.44 |
| MLR | ||||||
| Low | Ref | Ref | ||||
| High | 1.58 | 0.58–4.30 | 0.36 | 2.08 | 0.56–7.75 | 0.27 |
| d-NLR | ||||||
| Low | Ref | Ref | ||||
| High | 1.78 | 0.45–7.04 | 0.40 | 4.89 | 0.98–24.20 | 0.05 |
| PNI | ||||||
| Low | Ref | Ref | ||||
| High | 1.00 | 0.37–2.71 | 0.98 | 0.76 | 0.22–2.59 | 0.66 |
Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed death ligand 1; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; d-NLR, derived neutrophil-to-lymphocyte ratio; SII, systemic immune inflammation index; PIV, pan-immune inflammation value; PNI, prognostic nutritional index.